Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Taylor

Allergy & Immunology Madisonville, KY Medical Doctor

NPI 1295832913 CMS profile 149816

200 Clinic Dr, Madisonville, KY 42431

Open in the dashboard

General payments

$1,319

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Taylor of Madisonville, KY is reported in the CMS Open Payments database as having received $1,319 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $199 12
2024 General $226 13
2023 General $94 5
2021 General $37 3
2020 General $101 7
2019 General $664 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Taylor
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Frank Taylor were reported at $199. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Frank Taylor Allergy & Immunology median Middle half National median
2019 $664 $378 $115–$1,178 $163
2020 $101 $303 $75–$1,581 $114
2021 $37 $407 $122–$1,475 $132
2022 $0 $357 $120–$1,340 $149
2023 $94 $445 $124–$1,536 $160
2024 $226 $541 $129–$1,763 $164
2025 $199 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $187 12 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $155 10 payments
  3. Regeneron Healthcare Solutions, Inc. $129 8 payments
  4. Janssen Pharmaceuticals, Inc $120 11 payments
  5. Baxter Healthcare $114 5 payments
  6. Amgen Inc. $105 7 payments
  7. Genzyme Corporation $90 5 payments
  8. Grifols USA, LLC $48 3 payments
  9. Actelion Pharmaceuticals US, Inc. $48 3 payments
  10. AstraZeneca Pharmaceuticals LP $45 3 payments
  11. Other $278 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,292 83 payments
  2. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. LifeVest $155 10 payments
  2. TRELEGY ELLIPTA $132 9 payments
  3. XARELTO $120 11 payments
  4. Repatha $105 7 payments
  5. Corlanor $91 6 payments
  6. DUPIXENT Immunology $90 5 payments
  7. INVOKANA $67 7 payments
  8. DUPIXENT Immunology And Inflammation $67 4 payments
  9. DUPIXENT Inflammation And Immunology $62 4 payments
  10. Prolastin-C Liquid $48 3 payments
  11. Other $589 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,044

Median for Pulmonary Disease: 936

Drug cost

$352,808

Median for Pulmonary Disease: $487,987

Branded share of claims

52.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 306 $221,246
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 108 $68,567
Breo Ellipta Fluticasone/Vilanterol Brand 34 $13,124
Advair Hfa Fluticasone Propion/Salmeterol Brand 29 $8,880
Theophylline Er Theophylline Anhydrous Brand 85 $6,987
Albuterol Sulfate Hfa Albuterol Sulfate Brand 307 $5,365
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $4,693
Varenicline Tartrate Generic 17 $4,546
Doxycycline Monohydrate Generic 302 $4,078
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 51 $3,630

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$30,888

Of which drugs: $245

Medicare patients

153

Average age 73

Services billed

2,683

77 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 75%
Arthritis 60%
Ischemic heart disease 55%
Heart failure 46%
Chronic kidney disease 42%
Diabetes 40%
Depression 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 2,160 $213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $62
  • GENZYME CORPORATION $43
$105 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $59
$59 306 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record